LSD increases sleep duration the night after microdosing
In a Phase 1 randomized, double‑blind, placebo‑controlled trial of 80 healthy male volunteers, microdosing LSD (10 µg every third day for six weeks) increased objectively measured sleep duration by 24.3 minutes on the night after dosing compared with placebo, with no changes in sleep‑stage proportions or physical activity. The effect, observed across 3,231 nights, is clinically meaningful and unlikely to be explained by placebo.
Authors
- Suresh Muthukumaraswamy
- Rebecca Sumner
- Robin Murphy
Published
Abstract
Microdosing psychedelic drugs at a level below the threshold to induce hallucinations is an increasingly common lifestyle practice. However, the effects of microdosing on sleep have not been previously reported. Here, we report results from a Phase 1 randomized controlled trial in which 80 healthy adult male volunteers received a 6-week course of either LSD (10 µg) or placebo with doses self-administered every third day. Participants used a commercially available sleep/activity tracker for the duration of the trial. Data from 3231 nights of sleep showed that on the night after microdosing, participants in the LSD group slept an extra 24.3 min per night (95% Confidence Interval 10.3–38.3 min) compared to placebo—with no reductions of sleep observed on the dosing day itself. There were no changes in the proportion of time spent in various sleep stages or in participant physical activity. These results show a clear modification of the physiological sleep requirements in healthy male volunteers who microdose LSD. The clear, clinically significant changes in objective measurements of sleep observed are difficult to explain as a placebo effect. Trial registration: Australian New Zealand Clinical Trials Registry: A randomized, double-blind, placebo-controlled trial of repeated microdoses of lysergic acid diethylamide (LSD) in healthy volunteers; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=381476 ; ACTRN12621000436875.
Research Summary of 'LSD increases sleep duration the night after microdosing'
Introduction
Microdosing—the repeated self-administration of sub-hallucinogenic doses of psychedelics such as LSD or psilocybin—has become a popular practice with claimed benefits for mood, creativity and productivity. Previous controlled work on macrodoses of serotonergic psychedelics has shown effects on sleep architecture (for example altered REM sleep and slow-wave power), and some older or uncontrolled reports have suggested that low doses of LSD can modify REM and increase body movements during sleep. However, objective, prospectively collected measurements of sleep in contemporary microdosing regimens are lacking, and community surveys give mixed subjective reports about sleep quality following microdosing. Allen and colleagues therefore set out to evaluate whether microdosing LSD alters objective sleep and activity measures. They embedded sleep monitoring into a Phase I, double-blind, randomised, placebo-controlled trial in which healthy volunteers self-administered 10 µg LSD or placebo every third day for six weeks while wearing consumer-grade wearable devices to capture naturalistic sleep and activity data. The trial aimed to provide the first objective assessment of sleep changes associated with a standardised microdosing schedule in an ecologically valid, home-administered setting.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Allen, N., Jeremiah, A., Murphy, R., Sumner, R., Forsyth, A., Hoeh, N., Menkes, D. B., Evans, W., Muthukumaraswamy, S., Sundram, F., & Roop, P. (2024). LSD increases sleep duration the night after microdosing. Translational Psychiatry, 14(1). https://doi.org/10.1038/s41398-024-02900-4
References (19)
Papers cited by this study that are also in Blossom
Anderson, T., Petranker, R., Christopher, A. et al. · Harm Reduction Journal (2019)
Anderson, T., Petranker, R., Rosenbaum, D. et al. · Psychopharmacology (2019)
Barbanoj, M. J., Riba, J., Clos, S. et al. · Psychopharmacology (2007)
Bershad, A. K., Preller, K. H., Lee, R. et al. · Biological Psychiatry (2020)
Bershad, A. K., Schepers, S. T., Bremmer, M. P. et al. · Biological Psychiatry (2019)
Cavanna, F., Muller, S., de la Fuente, L. A. et al. · Translational Psychiatry (2022)
de Wit, H., Molla, H. M., Bershad, A. K. et al. · Addiction Biology (2022)
Dudysová, D., Janků, K., Šmotek, M. et al. · Frontiers in Pharmacology (2020)
Family, N., Maillet, E. L., Williams, L. T. J. et al. · Psychopharmacology (2019)
Glazer', J., Murray, C. H., Nusslock', R. et al. · Neuropsychopharmacology (2022)
Show all 19 referencesShow fewer
Hutten, N. R. P. W., Mason, N. L., Dolder, P. C. et al. · European Neuropsychopharmacology (2020)
Johnstad, P. G. · Nordic Studies on Alcohol and Drugs (2018)
Lea, T., Amada, N., Jungaberle, H. et al. · International Journal of Drug Policy (2020)
Marschall, J., Fejer, G., Lempe, P. et al. · Journal of Psychopharmacology (2021)
Murphy, R., Sumner, R. L., Evans, W. J. et al. · Biological Psychiatry (2023)
Perry, C. M., Malina, M. · Psychopharmacology (2021)
Ramaekers, J. G., Hutten, N. P. W., Mason, N. L. et al. · Journal of Psychopharmacology (2020)
Rootman, J. M., Kryskow, P., Harvey, K. et al. · Scientific Reports (2021)
Szigeti, B., Kartner, L., Blemings, A. et al. · eLife (2021)
Cited By (3)
Papers in Blossom that reference this study
Murphy, R. J., Wardlaw, M., Smith, T. et al. · Journal of Humanistic Psychology (2025)
Modzelewski, S., Waszkiewicz, N., Lukasiewicz, K. et al. · Neuropharmacology (2025)
Murphy, R., Muthukumaraswamy, S., De Wit, H. · Biological Psychiatry (2024)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.